> Detailanzeige

Zhou, Xiang; Steinhardt, Maximilian J.; Grathwohl, Denise; Meckel, Katharina; Nickel, Katharina; Leicht, Hans‐Benno; Krummenast, Franziska; Einsele, Hermann; Rasche, Leo; Kortüm, Klaus M.

Multiagent therapy with pomalidomide, bortezomib, doxorubicin, dexamethasone, and daratumumab (“Pom‐PAD‐Dara”) in relapsed/refractory multiple myeloma

Literatur-
verwaltung

Zur
Merkliste

Lösche von
Merkliste

Per Whatsapp teilen

Schließen

Merkliste



Sie können Bookmarks mittels Listen verwalten, loggen Sie sich dafür bitte in Ihr SLUB Benutzerkonto ein.
  • Medientyp: E-Artikel
  • Titel: Multiagent therapy with pomalidomide, bortezomib, doxorubicin, dexamethasone, and daratumumab (“Pom‐PAD‐Dara”) in relapsed/refractory multiple myeloma
  • Beteiligte: Zhou, Xiang; Steinhardt, Maximilian J.; Grathwohl, Denise; Meckel, Katharina; Nickel, Katharina; Leicht, Hans‐Benno; Krummenast, Franziska; Einsele, Hermann; Rasche, Leo; Kortüm, Klaus M.
  • Erschienen: Wiley, 2020
  • Erschienen in: Cancer Medicine
  • Sprache: Englisch
  • DOI: 10.1002/cam4.3209
  • ISSN: 2045-7634
  • Schlagwörter: Cancer Research ; Radiology, Nuclear Medicine and imaging ; Oncology
  • Entstehung:
  • Anmerkungen:
  • Beschreibung: <jats:title>Abstract</jats:title><jats:sec><jats:title>Background</jats:title><jats:p>Even in the era of novel immunotherapies for multiple myeloma (MM), treatment of late‐stage relapsed/refractory (RR) patients remains challenging. The aim of our study was to analyze the efficacy and safety of the five‐drug combination pomalidomide, bortezomib, doxorubicin, dexamethasone, and daratumumab (“Pom‐PAD‐Dara”) in RRMM.</jats:p></jats:sec><jats:sec><jats:title>Methods</jats:title><jats:p>We retrospectively analyzed data of 56 patients with RRMM who received Pom‐PAD‐Dara between September 2016 and May 2019.</jats:p></jats:sec><jats:sec><jats:title>Results</jats:title><jats:p>Patients were heavily pretreated with a median of four prior lines of therapy, including autologous and allogenic stem cell transplant in 50 (89%) and six (11%) patients, respectively. The overall response rate (ORR) was 78% and we observed partial remission, very good partial remission, and complete remission in 27 (48%), 13 (23%) and four (7%) patients, respectively. Median progression‐free survival was 7 months (95% CI, 3.3‐10.7) and the median overall survival was not reached at 24 months. Adverse events grade ≥ 3 were observed 41 (73%) patients and included neutropenia (n = 28, 50%), anemia (n = 22, 39%), thrombocytopenia (n = 21, 38%), and pneumonia (n = 6, 11%).</jats:p></jats:sec><jats:sec><jats:title>Conclusion</jats:title><jats:p>Pom‐PAD‐Dara represents a promising multiagent regimen in heavily pretreated RRMM patients with high ORR and an acceptable safety profile.</jats:p></jats:sec>
  • Zugangsstatus: Freier Zugang